207 results on '"Fransecky, Lars"'
Search Results
2. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities
3. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
4. Entwicklung einer akuten myeloischen Leukämie unter adjuvanter Therapie mit Olaparib nach neoadjuvanter Chemotherapie eines triple-negativen Mammakarzinoms – eine Kasuistik
5. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
6. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
7. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
8. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
9. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
10. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
11. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
12. Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL‐MODULE phase I study
13. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens
14. Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
15. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
16. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
17. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
18. Neural stem cell culture model for LRRK2 function determines regulation of dopaminergic and microtubule-associated genes
19. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)
20. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
21. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
22. Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
23. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
24. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
25. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
26. Intensified cytarabine dose during consolidation in AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
27. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
28. High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia
29. Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
30. Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study
31. Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
32. Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications
33. Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit
34. Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience
35. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
36. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
37. Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML
38. Additional file 1 of Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
39. Additional file 2 of Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
40. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
41. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRAactivation due to insulator disruption in acute myeloid leukemia (AML)
42. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification
43. Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial
44. Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols
45. Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)
46. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
47. Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia
48. Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial
49. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
50. DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.